Adaptimmune Therapeutics PLC (ADAP.OQ)
17 Nov 2017
* Adaptimmune reports third quarter 2017 financial results and business updates
* Matrix Capital Management Company Lp reports 12.9 percent passive stake in Adaptimmune Therapeutics Plc as of August 31, 2017 - SEC filing Source text: (http://bit.ly/2wSEc1U)
LONDON GlaxoSmithKline said it has licensed the rights to Adaptimmune's pioneering T-cell therapy program to boost its pipeline in oncology, one of four areas its has prioritized for research and development.
* Adaptimmune Therapeutics Plc - GSK exercises option over SPEAR T-cell therapy program targeting NY-ESO
* Adaptimmune announces an oral presentation on data from NY-ESO study in Synovial Sarcoma and four trials in progress posters at the American Society Of Clinical Oncology (ASCO) annual meeting